PRLog - Feb. 16, 2015 - ST. LOUIS -- Lee Biosolutions, Inc, a manufacturer and global provider of highly purified enzymes and related proteins for the life science, clinical diagnostic and the biotech healthcare industry, is proud to announce the addition of 3 new members to the Board of Directors reflecting its continued growth and expansion of the business.
President and CEO, J. Burton Lee says, “As a leader in the industry, we have a responsibility to maintain a strong articulated business strategy that will allow us to grow as our client base and product line continues to expand. I chose our members for their expertise, passion and commitment to make us a world class institution that will create a momentum in the market place that will be exciting for everyone doing business with us.”
New Board Members
Matthew P. Lee is currently Vice-President with responsibilities that include day to day operations of the business ensuring our company exceeds our customer expectations. Matthew holds a BS in Marketing Management from Missouri State University and joined Lee Biosolutions in 2012 as Logistics Manager. He was promoted to Vice-President in 2014 for his leadership and commitment to the business that has contributed to our highest growth in history of the company.
Daniel T. Fagan, PhD joined Lee Biosolutions in 2014 and brings a wealth of knowledge to the Board with his career spanning more than 37 years in both the Fine Chemical and Pharmaceutical Industries. His previous industrial experience includes the following: President of Sigma Chemical, General Manager of Mallinckrodt Peptides, President of PepTx, President, CEO and Chairman of the Board of Synthetech, Inc., Managing Director Brocair Partners as well as consulting over the last 15 years for various fine chemical, biotechnology and pharmaceutical companies.
Douglas D. Held, PhD joined Lee Biosolutions in 2010 and has focused on building the company’s core technical and scientific expertise and translating that expertise into new business opportunities. Doug has substantial experience in development and commercialization of processes for production and testing of biological molecules. Doug's previous experiences includes a leadership positions at Singulex, Inc. and Sigma Aldrich, Inc. Doug has been issued four patents for biochemical methods for detection of human disease. Doug received a B.S in Chemistry and Biology from Iowa State University and a PhD in Biochemistry from the University of Wisconsin, Madison, followed by post graduate training in Chemistry at the University of Iowa.
About Lee Bio
Lee Biosolutions is a producer of high purity finished enzymes and related proteins used by research institutions, IVD manufacturers and the biotech healthcare industries worldwide. LeeBio is known for its expertise, leadership and support by clients because of its ability to closely partner with them in the development, purification, scale up and commercialization of innovative products.
Read Full Story - Lee Biosolutions Expands Board Of Directors | More news from this source
Press release distribution by PRLog
Lee Biosolutions Expands Board Of Directors
February 16, 2015 at 15:46 PM EST